Annamycin (AnnAraC)
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 3Planned (MIRACLE Trial MB-108)
Key Facts
Indication
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase
Phase 3
Status
Planned (MIRACLE Trial MB-108)
Company
About Moleculin Biotech
Moleculin Biotech is a clinical-stage company focused on developing novel therapeutics for difficult-to-treat cancers and viruses, with a core mission to overcome the limitations of existing anthracyclines. Its key achievement is the advanced development of Annamycin, a next-generation, non-cardiotoxic anthracycline poised to enter a pivotal Phase 3 trial (MIRACLE) for relapsed/refractory AML. The company's strategy leverages a lean operational model and a multi-pronged pipeline to de-risk development and address significant unmet medical needs in oncology and virology.
View full company profileOther Relapsed or Refractory Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fosciclopirox (Ciclopirox Prodrug) | CicloMed | Phase 1B/2A |
| CPI-613 (devimistat) + Cytarabine/Mitoxantrone | Rafael Holdings | Phase 3 |